Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The rectum is the terminal segment of the large intestine, typically measuring between 12 and 15 cm in length, and serves as a temporary reservoir for feces before defecation [1, 2]. It is characterized by its role in the defecation reflex, where the stretching of the rectal walls signals the nervous system to initiate the urge to evacuate [1, 3]. While the rectum itself is an anatomical organ and not a specific molecular target, it is a primary site for significant diseases such as colorectal cancer and inflammatory bowel diseases like ulcerative proctitis [4]. In pharmacology, the rectum is a vital route for drug administration, particularly when oral intake is not possible or when localized treatment of the rectal mucosa is required [5]. Therapeutic agents such as mesalamine or corticosteroids are often delivered rectally to manage inflammation by interacting with molecular pathways within the intestinal lining [5].
Not applicable. The rectum is an anatomical organ rather than a molecular target; however, drugs administered to the rectum typically target inflammatory mediators (e.g., TNF-alpha) or provide local anesthesia by blocking sodium channels [1, 5].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rectum.